LCM
CPRX

Legato Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Legato Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$782K Hold
24,889
– – 0.06% 425
2026
Q1 		$616K Sell
24,889
-33,857
-58% -$807K 0.06% 481
2025
Q4 		$1.37M Buy
58,746
+10,488
+22% +$234K 0.12% 275
2025
Q3 		$951K Buy
48,258
+18,147
+60% +$373K 0.1% 304
2025
Q2 		$653K Sell
30,111
-23,541
-44% -$556K 0.08% 389
2025
Q1 		$1.3M Buy
+53,652
New +$1.21M 0.18% 187

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Legato Capital Management's CPRX Position: Q2 2026 in Review

Legato Capital Management held its Catalyst Pharmaceutical (CPRX) position steady in Q2 2026 at 24,889 shares worth $782K. The position accounts for 0.06% of the portfolio, ranked #425.

Legato Capital Management first reported a position in CPRX in Q1 2025 and has held it in 6 quarters since. The position peaked at $1.37M in Q4 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Legato Capital Management held 24,889 shares of Catalyst Pharmaceutical worth $782K as of Q2 2026.
  • Legato Capital Management left its Catalyst Pharmaceutical share count unchanged in Q2 2026.
  • Catalyst Pharmaceutical made up 0.06% of Legato Capital Management's portfolio in Q2 2026, its #425 holding.
  • Legato Capital Management first reported a position in Catalyst Pharmaceutical in Q1 2025 and has held it in 6 quarters since.
  • Legato Capital Management's Catalyst Pharmaceutical position peaked at $1.37M in Q4 2025.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.